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A Global Threat
In the last year, several institutions—the
World Health Organization (WHO), the
United Nations Office on Drugs and
Crime, and the United States Institute of
Medicine—have turned their attention,
with varying degrees of effectiveness, to
the problem of dangerously poor quality
medicines [1]. While substandard medi-
cines are found everywhere in the world, it
is the poorest countries with the weakest
capacity for drug regulation and quality
control that suffer the most.
Everyone agrees that poor quality
medicines are undesirable, but not every-
one agrees on how to define them. It is
clear that iatrogenic harm arises from at
least two distinct, concurrent problems: (i)
medicines that are accidentally or negli-
gently ‘‘substandard’’ as a result of various
failures in manufacturing, handling, regu-
lation, or some combination of these, and
(ii) medicines that are deliberately ‘‘falsi-
fied,’’—neither being of the correct stan-
dard nor being properly registered
through a country’s regulatory authori-
ty—and that call out for criminal law
measures to suppress. In all cases, the
result is a potentially dangerous medicine,
whether occasioned by criminal activity,
accident, or negligence [2].
A sound drug regulatory system is
essential to overcome these problems.
Yet while WHO estimates that nearly a
third of its member states have very
limited or no capacity for medicine
regulation [3], it has yet to propose a
concrete action plan to help ensure the
quality of national drug supplies [2].
Undermining Tuberculosis
Control
While the malaria community has
worked since the 1990s to address the
problem of poor quality drugs, the tuber-
culosis control community has come to it
late [4]. The available evidence suggests a
widespread problem with substandard and
falsified anti-tuberculosis drugs available in
low- and middle-income countries, but
little awareness that such a threat exists.
The global scope of the danger is
strongly hinted at by a study conducted
by some of the authors of this Essay [4].
Among 713 samples of isoniazid and
rifampicin purchased at community phar-
macies in 19 cities of 17 countries, 65
(9.1%) of the samples had insufficient
active pharmaceutical ingredient (API)
and failed basic quality control tests. Of
those samples 18 (of 65, or 27.7%) were
definitely falsified, since they had zero API
and obviously fake packaging. The re-
maining products with insufficient API (47
of 65, or 72.3%) were either substandard
or falsified; there is not evidence enough to
determine which, because these products
could have been faulty by accident (the
hallmark of substandard drugs) or faulty
by criminal intent (the hallmark of falsified
drugs), although both are dangerous.
Certainly, the most dangerous failures
are the 36 (55.4%) products that contained
more than trace amounts of isoniazid and
rifampicin, and that had an intermediate
dose (between 10% and 80%) likely
insufficient to cure disease, but definitely
capable of selecting the drug-resistant
bacilli that cause life-threatening multi-
drug-resistant and extensively drug-resis-
tant tuberculosis. The situation is even
worse in the study’s 11 African countries,
where 27 of 163 total samples (16.6%)
failed testing. Fifteen of these 27 failures
(44.4%) were probably substandard drugs,
while at least 12 (55.6%) were falsified
drugs. These findings were in line with
previous studies [5,6].
Rwanda’s Efforts to Ensure
Drug Quality
Rwanda was the only African nation
whose samples did not include any falsified
products. Rwanda has also performed
better than other African nations in other
large studies, having few substandard and
no obviously falsified products [4,7,8].
There are two probable reasons for this
success: first, the government of Rwanda
has taken concrete legal and technical
steps to ensure the quality of its drug
supply chain; second, Rwanda was able to
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do that because it brought tuberculosis
control into the publicly funded health
system to a greater extent than many
countries, which often rely on unregulated
treatment in larger private sectors.
Aware of the dangers of poor quality
drugs for tuberculosis and malaria, in the
late 1990s Rwanda mandated that all drug
contracts awarded by the Ministry of
Health must be to manufacturers with
current WHO-approved certificates of
Good Manufacturing Practices. Recent
research on artemisinin combination ther-
apies (ACTs) for malaria has shown that
products of WHO-approved manufactur-
ers are up to five times less likely to fail
basic quality tests [9].
Rwanda’s ‘‘Guidelines for Pharmacov-
igilance and Medicine Information System
in Rwanda’’ [10] were adopted in early
2011, and led to the formation of pharma-
covigilance sub-committees at all 469
health centers that are overseen by the
country’s 42 district hospitals. Standard-
ized notification forms for poor quality
health products are available to patients,
community health workers, nurses, physi-
cians, and pharmacists at health facilities,
where they are collected for periodic
review by the National Pharmacovigilance
and Medicine Information Center in the
Ministry of Health. To date, more than
2,400 health workers have been trained in
the implementation of the guidelines.
With the support of national and
international partners, the Ministry of
Health conducts quality control by testing
each imported drug shipment as well as
systematically sampling ACTs and anti-
tuberculosis drugs from each level of the
health sector on a quarterly and annual
basis, respectively. These medicines are
distributed via a dedicated supply chain
including climate-controlled storage facil-
ities and vehicles.
Rwanda has also largely succeeded in
prohibiting sales of malaria monotherapies
and all anti-tuberculosis drugs through
private pharmacies, where the provision of
monotherapies for both diseases poses a
major global regulatory challenge (both
infections respond best to combination
therapy). Private health facilities, however,
can continue to provide tuberculosis
treatment if they become accredited as
Centers for Diagnosis and Treatment of
Tuberculosis, which are integrated into
the public sector supply chain and provide
quality-assured drugs for free to tubercu-
losis patients. Private pharmacies can sell
ACTs to patients who have a prescription
from a health worker following a positive
diagnostic test.
Rwanda’s Bureau of Standards verifies
certification documents and, together with
the Customs Services Department and the
Ministry of Health, inspects each shipment
of drugs upon importation into the
country. Where falsified medicines are
found, these authorities partner with the
Rwandan police force and Interpol to
denounce and to try to arrest the orga-
nized criminals responsible. Thus, Rwan-
da’s drug quality control strategy depends
not only on its health system, but on its law
enforcement and justice systems as well.
Positive Signs and Next Steps
As policymakers in, and researchers of,
Rwanda’s health sector, we argue that the
improvement of the country’s supply chain
and drug surveillance systems, combined
with equity-oriented strategies for increas-
ing geographic and financial access to high
quality drugs through the public sector,
has played an important role in the
country’s steep declines in mortality due
to tuberculosis and malaria. Between 2000
and 2011, Rwanda’s tuberculosis mortality
rate declined 77.1%, and reported annual
malaria deaths dropped 85.3% from 2005
to 2011 [11]. Treatment success rates for
new smear-positive cases of drug-suscepti-
ble tuberculosis increased from 63% in
2000 to 88% in 2010 [12]. Further, 88%
of patients treated for multidrug-resistant
tuberculosis through 2011 had a successful
outcome [13], and the country has not yet
seen a case of extensively drug-resistant
tuberculosis.
Rwanda understands that the problems
of falsified and substandard drugs cannot
be effectively addressed by one institution
or one country working alone. It is
therefore contributing to the drafting of a
regional law against falsified medicines
with other member states of the East
African Community, and plans to advo-
cate for clear language distinguishing
between generic and falsified medicines.
Rwanda is also a party to the recently
launched East African Community Med-
icines Regulatory Harmonization Initia-
tive.
Time for Action
It is time for the tuberculosis control
community to recognize the causes and
consequences of falsified and substandard
drugs and to mobilize a global response.
Evidence-driven actions at the national
level are essential and should be supported
by multilateral donors, but will not be
sufficient to solve this global problem.
We propose that a global treaty is now
needed to guarantee sustainable progress
towards higher quality medicines by
bringing regulatory, technical, legal, and
financial mechanisms to bear together
[14]. Such a treaty will be possible only
with visionary and transparent leadership
from WHO on behalf of its member states
[2]. As the dangers of drug-resistant
tuberculosis fed by poor quality medicines
illustrate all too well, the world loses
ground with each passing day that WHO
delays.
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Summary Points
N Substandard and falsified medicines are major global health challenges that
cause unnecessary morbidity and mortality around the world and threaten to
undermine recent progress against infectious diseases by facilitating the
emergence of drug resistance.
N In a recent study, Rwanda had the lowest prevalence of poor quality
tuberculosis drugs among African countries in the sample. This positive finding
may be associated with Rwanda’s efforts to ban the sale of monotherapies,
ensure that private sellers of important medicines are qualified, and prioritize
the prevention of falsified medicines entering the country.
N Drawing on our experiences in Rwanda scaling up pharmacovigilance for
malaria and tuberculosis, we call for a global treaty and leadership by the World
Health Organization to address manufacturing and trade in substandard and
falsified medicines.
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